Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: GREG FINLEY who wrote (200)	6/11/1998 2:13:00 PM
From: Michael C. Woodward	Read Replies (2) \| Respond to of 534

Just got another report on Bioject that supports the comments made in the Dick Davis Digest of 5/4/98. "This stock could easily be in the 3 to5 range by year-end." "We recommended this stock as a speculation at $0.56 last summer, called it a repeat buy a few months ago at $1.38 and now we will repeat the recommendation at $1.81. This stock is headed for $5 in 1999." RE biojector - "the upside potential is enormous, especially when you stop to consider the number of injectable drugs which are on the market, all of which are candidates for pre-fill cartridges to be used in this modern delivery method." RE: Elan Joint Venture - "Preclincal trials have been very encouraging and this business by itself might be worth $5 per share in the next few years" "Besides the 17% ownership stake by Elan, Hambrecht & Quist owns just under 2 million shares of the company and a private money management firm owns about 2.4 million shares" (I like H&Q and am a very small member of a private money management team holding BJCT). "a director of the company has been taking the opportunity to increase his holdings in the past several months (69,000 shares). Nobody is doing any selling" "Since our last report on Bioject, the company has also completed successful preclinical trials of the glucose monitoring device on a small group of diabetics in Ireland and is now planning clinical trials which should begin in the next six to nine months." Investor's Business Daily EPS RS (Relative Strength) Recent 33 97 One Month Ago 33 97 Two Months Ago 33 91 Three Months Ago 33 83 An RS of 90 or better is very positive. RS measures daily each stock's relative price change over the last 12 months compared to all other stocks in the tables (NASDAQ). Results are ranked 1 to 99. Stocks ranking below 70 indicate weaker or more laggard relative price performance.